Slicing through the fog of neurodegeneration with cutting-edge tools: feedback from ASNR22

ASNR22 provided a great opportunity to discuss tools that would help neuroradiologists support their referring clinicians when diagnosing patients with symptoms of dementia. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, and Greg Kingston, Combinostics Chief Marketing Officer (CMO).

Continue ReadingSlicing through the fog of neurodegeneration with cutting-edge tools: feedback from ASNR22

Preserving the mind: key takeaways from AAN 2022

AAN 2022 highlighted cutting-edge research in neurology and provided opportunities for networking within the neurology community. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from advances for traumatic brain injury to the future of AI and neurology.

Continue ReadingPreserving the mind: key takeaways from AAN 2022

The future of MS biomarkers: key takeaways from ACTRIMS 2022

ACTRIMS 2022 highlighted novel scientific discoveries for multiple sclerosis (MS), with a focus on MS biomarkers. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from better, novel treatments to the potential of enhanced AI-based neuroimaging for improved patient management.

Continue ReadingThe future of MS biomarkers: key takeaways from ACTRIMS 2022

Meet the Team: Peter Ngum, Clinical Application Specialist

In the third edition of our “Meet the Team” blog series, we talk to Peter Ngum, one of Combinostics’ Clinical Application Specialists, about his academic and industry experience, what he loves about his role, and some fascinating conferences he’s attended recently.

Continue ReadingMeet the Team: Peter Ngum, Clinical Application Specialist

Early detection and differentiation of dementias: with AI, vast amounts of data are an asset, not a burden

Although detection of and differentiation among the various types of dementia remain challenging for clinicians, technological advances such as artificial intelligence (AI) and machine learning (ML) can help.

Continue ReadingEarly detection and differentiation of dementias: with AI, vast amounts of data are an asset, not a burden